Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of 1.92% is 56% above its 5-year average of 1.23%, near the high end of its 5-year range (-432.20%–10.38%).
39.35% below its 12-month average of 3.17%.
Reported quarterly profit margin; no daily interpolation. Q1 FY2027 (2026-06-30): 4.71%.
NET PROFIT MARGIN
1.92%
NET PROFIT MARGIN AVG TTM
3.17%
NET PROFIT MARGIN AVG 3Y
1.17%
NET PROFIT MARGIN AVG 5Y
1.23%
NET PROFIT MARGIN AVG 10Y
3.95%
NET PROFIT MARGIN AVG 15Y
8.08%
NET PROFIT MARGIN AVG 20Y
11.54%
CURRENT VS TTM AVG
-39.35%
CURRENT VS 3Y AVG
+64.28%
CURRENT VS 5Y AVG
+55.95%
CURRENT VS 10Y AVG
-51.38%
CURRENT VS 15Y AVG
-76.23%
CURRENT VS 20Y AVG
-83.37%
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 836 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Mesa Laboratories, Inc.
Market Cap
$765.23M
Net Profit Margin
1.92%
TTM Avg
3.17%
3Y Avg
1.17%
5Y Avg
1.23%
Market Cap
$768.46M
Net Profit Margin
-147.38%
TTM Avg
-372.93%
3Y Avg
-22199.44%
5Y Avg
-19748.48%
Market Cap
$761.20M
Net Profit Margin
-4490.89%
TTM Avg
-2245.45%
3Y Avg
-2245.45%
5Y Avg
-2245.45%
Market Cap
$771.06M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$747.61M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$784.66M
Net Profit Margin
-14.52%
TTM Avg
7.87%
3Y Avg
-15.98%
5Y Avg
-254.57%
Market Cap
$785.86M
Net Profit Margin
-34.17%
TTM Avg
-136.69%
3Y Avg
-25443.25%
5Y Avg
-23332.75%
Market Cap
$789.11M
Net Profit Margin
-7.58%
TTM Avg
0.29%
3Y Avg
-4.57%
5Y Avg
-4.54%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Mesa Laboratories, Inc. (MLAB) | $765.23M | 1.92% | 3.17% | 1.17% | 1.23% |
| Apnimed, Inc. (APMD)vs › | $767.19M | N/A | N/A | N/A | N/A |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $768.46M | -147.38% | -372.93% | -22199.44% | -19748.48% |
| Attovia Therapeutics, Inc. (ATTO)vs › | $761.20M | -4490.89% | -2245.45% | -2245.45% | -2245.45% |
| Sana Biotechnology, Inc. (SANA)vs › | $771.06M | 0.00% | 0.00% | 0.00% | 0.00% |
| Design Therapeutics, Inc. (DSGN)vs › | $747.61M | 0.00% | 0.00% | 0.00% | 0.00% |
| Gyre Therapeutics, Inc. (GYRE)vs › | $784.66M | -14.52% | 7.87% | -15.98% | -254.57% |
| Geron Corporation (GERN)vs › | $785.86M | -34.17% | -136.69% | -25443.25% | -23332.75% |
| AdaptHealth Corp. (AHCO)vs › | $789.11M | -7.58% | 0.29% | -4.57% | -4.54% |
| Candel Therapeutics, Inc. (CADL)vs › | $728.31M | 0.00% | 0.00% | -3758.80% | -9679.73% |
Operating Margin
9.0%
Net Profit Margin
1.9%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 4.71% |
| 2026-03-31 | -6.49% |
| 2025-12-31 | 5.57% |
| 2025-09-30 | 4.08% |
| 2025-06-30 | 7.96% |
| 2025-03-31 | -11.45% |
| 2024-12-31 | -2.67% |
| 2024-09-30 | 5.93% |
| 2024-06-30 | 5.82% |
| 2024-03-31 | -432.20% |
| 2023-12-31 | 3.96% |
| 2023-09-30 | -2.31% |
| 2023-06-30 | -1.08% |
| 2023-03-31 | 1.10% |
| 2022-12-31 | 0.83% |
| 2022-09-30 | 2.22% |
| 2022-06-30 | -2.85% |
| 2022-03-31 | -3.03% |
| 2021-12-31 | -3.77% |
| 2021-09-30 | 10.38% |
| 2021-06-30 | 5.71% |
| 2021-03-31 | 10.33% |
| 2020-12-31 | -13.29% |
| 2020-09-30 | 8.41% |
| 2020-06-30 | 4.06% |
| 2020-03-31 | -4.91% |
| 2019-12-31 | -14.23% |
| 2019-09-30 | 11.99% |
| 2019-06-30 | 17.49% |
| 2019-03-31 | 5.30% |
| 2018-12-31 | 3.22% |
| 2018-09-30 | 4.00% |
| 2018-06-30 | 16.82% |
| 2018-03-31 | 15.83% |
| 2017-12-31 | -46.83% |
| 2017-09-30 | 10.25% |
| 2017-06-30 | 6.69% |
| 2017-03-31 | 14.99% |
| 2016-12-31 | 13.64% |
| 2016-09-30 | 9.66% |
| 2016-06-30 | 9.14% |
| 2016-03-31 | 16.08% |
| 2015-12-31 | 11.86% |
| 2015-09-30 | 8.05% |
| 2015-06-30 | 12.70% |
| 2015-03-31 | 12.06% |
| 2014-12-31 | 13.48% |
| 2014-09-30 | 16.50% |
| 2014-06-30 | 11.47% |
| 2014-03-31 | 22.03% |
| 2013-12-31 | 13.31% |
| 2013-09-30 | 15.24% |
| 2013-06-30 | 16.58% |
| 2013-03-31 | 19.98% |
| 2012-12-31 | 13.58% |
| 2012-09-30 | 19.20% |
| 2012-06-30 | 19.88% |
| 2012-03-31 | 18.06% |
| 2011-12-31 | 21.46% |
| 2011-09-30 | 22.10% |
| 2011-06-30 | 18.89% |
| 2011-03-31 | 21.85% |
| 2010-12-31 | 16.44% |
| 2010-09-30 | 18.43% |
| 2010-06-30 | 17.71% |
| 2010-03-31 | 21.60% |
| 2009-12-31 | 21.70% |
| 2009-09-30 | 22.99% |
| 2009-06-30 | 20.61% |
| 2009-03-31 | 22.03% |
| 2008-12-31 | 22.78% |
| 2008-09-30 | 23.82% |
| 2008-06-30 | 20.10% |
| 2008-03-31 | 20.64% |
| 2007-12-31 | 24.30% |
| 2007-09-30 | 26.27% |
| 2007-06-30 | 23.68% |
| 2007-03-31 | 27.20% |
| 2006-12-31 | 19.98% |
| 2006-09-30 | 21.79% |
| 2006-06-30 | 21.50% |
| 2006-03-31 | 24.04% |
| 2005-12-31 | 23.24% |
| 2005-09-30 | 27.05% |
| 2005-06-30 | 22.13% |
| 2005-03-31 | 21.86% |
| 2004-12-31 | 22.25% |
| 2004-09-30 | 23.45% |
| 2004-06-30 | 24.62% |
| 2004-03-31 | 24.13% |
| 2003-12-31 | 22.74% |
| 2003-09-30 | 23.21% |
| 2003-06-30 | 23.22% |
| 2003-03-31 | 21.14% |
| 2002-12-31 | 24.52% |
| 2002-09-30 | 27.18% |
